申请人:Takeda Pharmaceutical Company Limited
公开号:EP1650201A1
公开(公告)日:2006-04-26
A compound represented by the formula [1]:
wherein ring A and ring B each represent an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl group optionally substituted with an optionally substituted hydroxyl group; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, -O- or -S-; X3 represents a bond or an optionally substituted divalent hydrocarbon group; Y represents an optionally esterified or amidated carboxyl group, or a salt thereof. The compound of the formula [I] is safer and has more potent lipid lowering activity such as squalene synthase inhibitory activity (cholesterol lowering activity) and triglyceride lowering activity, and thus it is a compound useful as an agent for preventing or treating hyperlipemia.
由式 [1] 表示的化合物:
其中,环 A 和环 B 各代表一个任选取代的苯环;环 C 代表一个任选进一步取代的芳环;R1 代表一个任选被羟基取代的低级烷基;X1a 代表一个键或任选取代的低级亚烷基;X1b 代表一个键或任选取代的低级亚烷基;X2 代表一个键、-O- 或-S-;X3 代表一个键或任选取代的二价烃基;Y 代表一个任选酯化或酰胺化的羧基或其盐。式[I]化合物更安全,具有更强的降脂活性,如角鲨烯合成酶抑制活性(降胆固醇活性)和降甘油三酯活性,因此它是一种可用于预防或治疗高脂血症的化合物。